S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

por Kater, Arnon, Dubois, Julie, Brieghel, Christian, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit, Mous, Rogier, Mellink, Clemens, Dobber, Johan, Poulsen, Christian, Da Cunha-Bang, Caspar, Fredriksen, Hendrik, Janssens, Ann, Schjodt, Ida, Dompeling, Ellen, Ranti, Juha, Mattsson, Mattias, Bellido, Mar, Tran, Hoa, Nasserinejad, Kazem, Levin, Mark-David, Niemann, Carsten
Publicado 2023